10-QPeriod: Q1 FY2021

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2021

Filed May 5, 2021For Securities:ABT

Summary

Abbott Laboratories reported a strong first quarter for 2021, with net sales surging 35.3% to $10.46 billion, significantly driven by its Diagnostics segment, which more than doubled its sales year-over-year. This dramatic growth in diagnostics was primarily fueled by the company's COVID-19 testing portfolio, including BinaxNOW, Panbio, and ID NOW platforms, which generated approximately $2.2 billion in sales for the quarter. Excluding COVID-19 testing-related sales, Abbott's overall net sales still showed robust growth of 5.7%, indicating broad-based strength across its business segments. The company's profitability also saw substantial improvement, with Net Earnings rising to $1.79 billion, or $1.00 per diluted share, compared to $564 million, or $0.31 per diluted share, in the prior year period. This enhanced performance was supported by increased sales volumes, improved manufacturing utilization, and a higher gross profit margin of 53.0%. Abbott also demonstrated effective cost management, with Selling, General & Administrative expenses rising at a slower pace than revenue. The company's financial health remains solid, with cash and cash equivalents increasing to $8.1 billion, providing ample liquidity for operations and future investments.

Financial Highlights

50 data points
Beta

Revenue

$10.46B

57.9% Gross Margin

Net Income

$1.79B

17.1% Net Margin

EPS (Diluted)

$1.00

Total Assets

$72.78B

Cash & Equivalents

$8.05B

Free Cash Flow

$2.24B

Financial Statements
Beta
Revenue$10.46B
Cost of Revenue$4.40B
Gross Profit$6.05B
R&D Expenses$654.00M
SG&A Expenses$2.78B
Operating Expenses$8.35B
Operating Income$2.11B
Interest Expense$135.00M
Net Income$1.79B
EPS (Basic)$1.00
EPS (Diluted)$1.00
Shares Outstanding (Basic)1.78B
Shares Outstanding (Diluted)1.79B

Key Highlights

  • 1Net sales increased by a significant 35.3% to $10.46 billion, driven by broad segment growth.
  • 2The Diagnostics segment experienced exceptional growth, with sales up 119.8% to $4.01 billion, largely due to a substantial ramp-up in COVID-19 testing sales.
  • 3COVID-19 testing sales reached approximately $2.2 billion, primarily from BinaxNOW, Panbio, and ID NOW platforms.
  • 4Excluding COVID-19 testing sales, underlying business growth was a healthy 5.7%, indicating sustained demand across other product lines.
  • 5Net earnings more than tripled to $1.79 billion, translating to a diluted EPS of $1.00, up from $0.31 in the prior year.
  • 6Gross profit margin improved to 53.0% from 50.3% in the prior year, reflecting higher sales volume and manufacturing efficiencies.
  • 7The company generated strong operating cash flow of $2.64 billion and ended the quarter with $8.05 billion in cash and cash equivalents.

Frequently Asked Questions

The primary driver of Abbott's significant revenue increase was the exceptional performance of its Diagnostics segment, which saw sales surge by 119.8%. This growth was largely fueled by the company's COVID-19 testing portfolio, which generated approximately $2.2 billion in sales during the quarter. Specifically, the BinaxNOW, Panbio, and ID NOW rapid testing platforms were key contributors.

Abbott's profitability saw a substantial improvement. Net earnings increased more than threefold to $1.79 billion in the first quarter of 2021, up from $564 million in the first quarter of 2020. This resulted in a significant rise in diluted earnings per share to $1.00, compared to $0.31 in the prior year. The improvement was driven by higher sales volumes, enhanced gross profit margins, and efficient cost management.

The filing acknowledges the unpredictability of the pandemic's duration and impact. While COVID-19 testing sales significantly boosted Q1 2021 results, Abbott is also focused on underlying growth in its other business segments. The company continues to innovate in diagnostics, receiving Emergency Use Authorizations for new tests and expanding their applications, indicating an ongoing commitment to this product area. However, the long-term reliance on COVID-19 testing revenue remains uncertain.

The Medical Devices segment demonstrated solid growth, with net sales increasing by 13.1% (8.8% excluding foreign exchange) to $3.32 billion. Key drivers included double-digit growth in Diabetes Care, primarily from the FreeStyle Libre continuous glucose monitoring system ($829 million in sales, up 29.8% excluding FX), and Structural Heart products like TriClip and MitraClip. Rhythm Management and Electrophysiology also contributed positively, although Heart Failure and Vascular segments experienced slight declines.